The Inflation Reduction Act is unlikely to generate savings for taxpayers, while disrupting the market and creating perverse ...

The guidelines took years to finalize, but while regulators were drafting them, a new trend emerged: online pharmaceutical ...

Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, ...

The rise in type 2 diabetes cases globally presents opportunities for growth in the market for GLP-1 drugs like Ozempic and ...